Gateway Pundit reports that, “a young boy has died due to cardiac arrest after receiving the company’s experimental gene therapy for Duchenne muscular dystrophy.
“A Pfizer spokesperson told Reuters in an exclusive email, “A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study.
“Pfizer’s gene therapy trial is currently testing children two to three-year-olds who have Duchenne muscular dystrophy.”
To read the whole Gateway Pundit story, click HERE.
